Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing Sites in San Diego and Bristol

Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing Sites in San Diego and Bristol

January 04, 2018PR-M01-18-NI-011-4917

Goettingen, Germany, January 04, 2018 / B3C newswire / Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.

Abzena has selected Sartorius Stedim to equip its integrated CDMO facilities in Bristol, PA (development and GMP manufacture of antibody drug conjugates) and San Diego, CA (development and GMP manufacture of monoclonal antibodies and other recombinant proteins).

Sartorius Stedim will provide both facilities with end-to-end process solutions in single-use (SU) format. It will equip Abzena’s San Diego process development lab with leading industry technologies such as Ambr250, enabling fast scale up to 500L initially and later to the 2000L scale single-use bioreactor for its centre of excellence in clinical manufacturing.

John Burt, Abzena CEO, commented: “In addition to having selected Sartorius’ industry leading single-use technologies for antibody and ADC production, the Abzena facilities will feature Umetrics process analytics software throughout the process ensuring that all the data captured throughout our clients’ molecule development is transformed into process knowledge ensuring that we can rapidly develop a robust and reliable process that can be easily scaled up to ensure a smooth technology transfer.”

Reinhard Vogt, Sartorius Executive VP commented: “We are pleased to have been selected by Abzena, a prominent global CDMO with a comprehensive industry portfolio across a wide range of modalities to supply single-use solutions that enable process development, tech transfer and GMP manufacturing. We look forward to working together to best serve the US and international markets.” 



Contact
Petra Kirchhoff
Sartorius Stedim Biotech
Vice President of Corporate Communications
Tel: +49(0)551.308.1686 
Email: petra.kirchhoff@sartorius.com 
www.sartorius-stedim.com

 

chat button